Dario Scimeca - 01 May 2024 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
General Counsel and Secretary
Signature
/s/ Dario Scimeca
Issuer symbol
DTIL
Transactions as of
01 May 2024
Net transactions value
-$2,807
Form type
4
Filing time
03 May 2024, 18:33:56 UTC
Previous filing
22 Apr 2024
Next filing
08 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +918 +18% 5,952 01 May 2024 Direct F1, F2, F3
transaction DTIL Common Stock Sale $2,807 -272 -4.6% $10.32 5,680 02 May 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Sale $0 -918 -50% $0.000000 919 01 May 2024 Common Stock 918 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F3 On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.
F4 The sales were effected pursuant to a Rule 10b5-1 plan adopted on July 14, 2023. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F6 On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.